Timed Response to Inhaled Nitric Oxide in Pulmonary Hypertension

PVRI Member Authors: David Badesch, Todd Bull


Pulmonary arterial hypertension (PAH) is a progressive, debilitating, and frequently terminal disease of the pulmonary vasculature.1 Over the past 20 years, the introduction of medications including calcium channel blockers (CCBs), phosphodiesterase-5 inhibitors (PDE5i), endothelin receptor antagonists (ERA), and prostacyclin therapies have significantly improved the treatment and prognosis of PAH.2 Despite these advancements, however, many patients continue to suffer unacceptably high morbidity and mortality.3 In light of this fact, it is notable that a subset (~5%–10%) of patients with idiopathic pulmonary arterial hypertension (IPAH) can respond to oral CCBs and have a significantly improved prognosis.4

Read the full article online


Nitric Oxide and Nitric Oxide Synthase
Pulmonary Arterial Hypertension


James M. Hunt, Michael G. Risbano, John C. Messenger, John Carroll, David Badesch, Brian D. Lowes, Ivan P. Casserly, Joseph Kay, Todd M. Bull

Published in:

Pulmonary Circulation Vol 4: No 1 cover image

March 2014

Pulmonary Circulation Vol 4: No 1

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI